Table 4 Baseline Characteristics of the cohort/all patients
Characteristic | N = 818 |
|---|---|
Age (mean ± SD, median, q25-q75) | 33.86 ± 4.85, 34, 31–37 |
BMI (mean ± SD, median, q25-q75) | 24.5 ± 4, 23.64, 21.87–26.18 |
No. of foetuses at observed gestation (N, % and 95 CI) | |
1 | 767 (93.77%, CI: 91.90–95.23%) |
≥ 2 | 51 (6.23%, CI: 4.77–8.10%) |
Delivery by CS (N, %) | 644 (78.7) |
Reason for enrolling in the study | |
Group A: History of VTE (DVT/SVT/Arterial thrombosis/Arterial Ischemia) | 76 (9.29%, CI: 7.49–11.47%) |
Group B: History of Pregnancy complications | 445 (54.40%, CI: 50.97–57.78%) |
Early pregnancy losses | 396 (88.99%, CI: 85.74–91.57%) |
Pregnancy losses < 3–3 or more | 348–48 |
IUGR | 10 (2.25%, CI: 1.23–4.09%) |
Fetal death | 28 (6.29, CI: 4.39–8.94%) |
Pre-eclampsia/eclampsia | 10 (2.25%, CI: 1.23–4.09%) |
Preterm labor/placenta abruption | 1 (0.22%, CI: 0.04–1.25%) |
Group C: IVF | 132 (16.14%, CI: 13.78–18.82%) |
Group D: Other reasons | 165 (20.17%, CI: 17.56–23.06%) |
Family History of VTE | 73 (44.24%, CI: 36.88–51.96%) |
Asymptomatic Hereditary Thrombophilia | 45 (27.27%, CI: 21.05–34.52%) |
Increased resistance in uterine arteries | 2 (1.21%, CI: 0.03–4.31%) |
Reasons not specified | 45 (27.27%, CI: 21.05–34.52%) |
Mean Duration of LMWH (months) (mean ± SD, median, q25-q75) | 8.63 ± 1.49, 9, 9–9.5 |
Concomitant Use of ASA (N, % and 95 CI) | 152 (18.58%, CI: 16.06–21.39%) |
Mean Duration of ASA (months) (mean ± SD, median, q25-q75) | 6.21 ± 2.56, 7, 3–8 |